Swedbank decreased its position in Celgene Corporation (NASDAQ:CELG) by 0.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,593,880 shares of the biopharmaceutical company’s stock after selling 1,896 shares during the period. Celgene Corporation makes up about 2.3% of Swedbank’s portfolio, making the stock its 15th biggest holding. Swedbank owned about 0.33% of Celgene Corporation worth $336,867,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of CELG. Sowell Financial Services LLC raised its stake in shares of Celgene Corporation by 0.5% during the 1st quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 13 shares during the last quarter. South Texas Money Management Ltd. raised its stake in shares of Celgene Corporation by 0.6% during the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares during the last quarter. Flagship Harbor Advisors LLC raised its stake in shares of Celgene Corporation by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares during the last quarter. Keel Point LLC raised its stake in shares of Celgene Corporation by 0.9% during the 1st quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 28 shares during the last quarter. Finally, Steinberg Global Asset Management raised its stake in shares of Celgene Corporation by 0.6% during the 1st quarter. Steinberg Global Asset Management now owns 6,594 shares of the biopharmaceutical company’s stock valued at $820,000 after buying an additional 39 shares during the last quarter. Institutional investors own 79.33% of the company’s stock.

Shares of Celgene Corporation (CELG) traded up 0.79% during mid-day trading on Monday, reaching $145.02. The company’s stock had a trading volume of 2,172,131 shares. The company has a market capitalization of $113.46 billion, a price-to-earnings ratio of 44.91 and a beta of 1.89. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $146.13. The firm’s 50 day moving average price is $135.45 and its 200-day moving average price is $127.81.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same period last year, the firm posted $1.44 earnings per share. On average, analysts predict that Celgene Corporation will post $7.32 EPS for the current year.

A number of research firms have weighed in on CELG. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $175.00 price objective (up previously from $148.00) on shares of Celgene Corporation in a research note on Monday, July 31st. Cantor Fitzgerald set a $160.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, July 27th. BMO Capital Markets reiterated an “outperform” rating and set a $160.00 price objective (up previously from $152.00) on shares of Celgene Corporation in a research note on Friday, July 28th. BidaskClub upgraded Celgene Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research note on Tuesday, June 6th. One analyst has rated the stock with a sell rating, seven have given a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $149.34.

ILLEGAL ACTIVITY WARNING: “Celgene Corporation (CELG) Shares Sold by Swedbank” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/25/celgene-corporation-celg-shares-sold-by-swedbank.html.

In other news, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the transaction, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,506 shares of company stock worth $6,019,761. 0.95% of the stock is currently owned by insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.